Clinical study of talazoparib/Tazena in the treatment of prostate cancer

Talazoparib is an oral PARP inhibitor that inhibits the DNA repair mechanism of tumor cells, making prostate cancer cells with BRCA1/2 or homologous recombination repair deficiency (HRD) more sensitive to DNA damage, thereby inhibiting tumor growth and spread. In recent years, clinical studies on patients with advanced or recurrent prostate cancer have shown that talazoparib has a positive effect in delaying disease progression and improving progression-free survival (PFS).

Clinical trials and multicenter observational studies have shown that talazoparib can produce hematological and imaging improvements while reducing cancer-related symptoms in prostate cancer patients who have previously received hormone therapy or chemotherapy. Compared with traditional chemotherapy,PARP inhibitors have relatively little impact on patients' quality of life while controlling disease progression. Some studies have also explored the combination of talazoparib with other drugs such as enzalutamide or abiraterone. Preliminary data show that combination therapy may further enhance the efficacy and improve the clinical prognosis of relapsed or refractory patients.

In addition, the application of talazoparib in genetically selected patients highlights the advantages of precision medicine. Patients with BRCA or HRD mutations confirmed through genetic testing can use PARP inhibitors in a targeted manner to improve efficacy and reduce unnecessary side effects. This personalized treatment concept has received increasing attention in modern tumor management, providing new strategies and possibilities for prostate cancer treatment.

Overall, talazoparib has shown significant anti-tumor effects in clinical studies of prostate cancer, and is especially suitable for relapsed or refractory patients with genetic defects. It is an important component of precision medicine and personalized treatment.

Reference materials:https://www.talzenna.com/